Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Phosphodiesterase type 4 (PDE4) inhibition is a well-known anti-inflammatory mechanism. However, the clinical use of PDE4 inhibitors has been compromised by the occurrence of mechanism-associated adverse reactions, which often limit the maximum tolerated dose. To minimize systemic exposure, a topically active PDE4 inhibitor with low transdermal bioavailability could be clinically useful. The purpose of this study was to evaluate the efficacy of a novel topical PDE4 inhibitor, E6005, in patients with atopic dermatitis. METHODS: This randomized, investigator-blinded, vehicle-controlled, multiple ascending dose study included 40 adult male patients with atopic dermatitis, who were randomly assigned to 10 days of treatment with either E6005 ointment (0.01, 0.03, 0.1 or 0.2%) or vehicle ointment. RESULTS: Of 81 patients screened, 40 who had typical lesions on their posterior trunk were randomized into the study. One patient receiving 0.03% E6005 treatment discontinued because of acute gout and one receiving vehicle treatment discontinued because of progression of atopic dermatitis. The targeted lesion severity scores decreased in a concentration-dependent manner in patients treated with E6005. This drop was significant in the 0.2% E6005 ointment treatment group (mean percent change: -54.30%, p = 0.007). CONCLUSION: E6005 ointment showed anti-inflammatory efficacy in adult patients with atopic dermatitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200 · cited 3×
“Histamine binding to the H1 receptor does not affect the cAMP-protein kinase A-dependent pathway, but it does affect phospholipase C-dependent pathways, which results in allergic reaction hypersensitivity responses, including redness, itching and swelling (20).”
BackgroundMethodInfluentialRegulation of the immune response and inflammation by histamine and histamine receptors
O’Mahony, L., Akdis, M., & Akdis, C. A. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.051 · Cited by 313 · cited 1×
“PDE4 inhibitors do not affect histamine-induced itch, but may alter itching caused by other mechanisms, such as serine proteases and proteinase-activated receptor 2 (23).”
BackgroundGrewe, S. R., Chan, S. C., & Hanifin, J. M. (1982) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(82)90008-2 · Cited by 230 · cited 1×
“PDE4 activity is elevated in the leukocytes of patients with AD (10), and it reduces cyclic adenosine monophosphate (cAMP) responses to stimulation (11), leading to leukocyte hyperactivity and inflammation (12,13).”
BackgroundFurue, M., Kitahara, Y., Akama, H., Hojo, S., Hayashi, N., Nakagawa, H., & The JAPANESE E6005 Study Investigators (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12534 · Cited by 77
Self-citation
Cited by
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580
Rerknimitr, P., Otsuka, A., Nakashima, C., & Kabashima, K. (2017) · Inflammation and Regeneration · doi:10.1186/s41232-017-0044-7 · Cited by 187
“Topical PDE-4 inhibitors, e.g., crisaborole [194] and E6005 [195], demonstrate clinical efficacy for AD in phase II and III clinical trials, respectively.”
Background
Metadata
- Authors
- Ohba, F., Matsuki, S., Imayama, S., Matsuguma, K., Hojo, S., Nomoto, M., & Akama, H.
- Venue
- Journal of Dermatological Treatment
- Publisher
- Informa UK Limited
- Published
- 2016-04-14
- Volume
- 27
- Issue
- 5
- Pages
- 467-472
- ISSN
- 0954-6634 (ISSN-L)
- 1471-1753
- OpenAlex
- W2340209106
- Cited by
- 44
- References
- 4
- FWCI
- 8.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study. https://app.cochat.ai/papers/10.3109/09546634.2016.1157257
- The paper
- Ohba, F., Matsuki, S., Imayama, S., Matsuguma, K., Hojo, S., Nomoto, M., & Akama, H. (2016). Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study. Journal of Dermatological Treatment. https://doi.org/10.3109/09546634.2016.1157257
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.